Tech Enhanced Investing

Tech Mahindra was trading at Rs 1601.30 on the BSE, registering a gain of Rs 4.30 or 0.27% compared with its previous close of Rs 1597.00.

The stock opened at Rs 1609.65 during the session and moved between an intraday high of Rs 1622.25 and a low of Rs 1600.00. A total of 20,352 shares changed hands on the counter.

The BSE Group 'A' company, with a face value of Rs 5 per share, has recorded a 52-week high of Rs 1850.00 on February 3, 2026, while its 52-week low of Rs 1304.25 was recorded on March 9, 2026.

Over the past week, the stock has traded between Rs 1592.35 and Rs 1649.10. The company's current market capitalisation stands at approximately Rs 1,56,948.82 crore.

As per the latest shareholding pattern, promoters hold 34.97% of the company, while institutional investors and non-institutional investors own 55.74% and 9.30%, respectively.

Tech Mahindra Expands Focus on Agentic AI

Tech Mahindra has announced the launch of its Amazon Web Services (AWS) Agentic Process Transformation (APT) Center of Excellence (CoE), aimed at helping enterprises adopt Agentic AI solutions at scale.

The new center will focus on developing and deploying practical AI solutions designed to deliver measurable business outcomes across multiple industries. By bringing together Tech Mahindra BPS's process expertise with AWS cloud infrastructure and Agentic AI capabilities, the initiative seeks to help businesses transition from experimental AI projects to production-ready implementations.

The AWS APT CoE is being positioned as a scalable AI execution platform that can support industry-specific use cases. Its solutions are expected to help enterprises improve operational productivity, optimise costs, strengthen decision-making and shorten the time required to move AI initiatives from pilot stages into production.

The initiative will also deepen Tech Mahindra's collaboration with AWS and enhance its capabilities in delivering enterprise-grade, governed AI transformation. Key sectors targeted through the initiative include telecommunications, healthcare, banking and financial services, retail and manufacturing.

According to the company, the launch will further support Tech Mahindra BPS's AWS-focused AI services strategy by creating new customer opportunities, expanding scalable delivery capabilities and speeding up AI engagements through sector-specific solutions.

Tech Mahindra provides technology consulting and digital transformation services to enterprises worldwide, helping organisations adopt technology solutions and scale their operations.

Cipla is witnessing a modest rise in its share price, trading at RS 1,390.90 on the BSE, representing a gain of RS 1.90 or 0.14% over its previous close of RS 1,389.00.

The stock began the session at RS 1,398.00 and moved between a high of RS 1,398.00 and a low of RS 1,377.00. Around 14,167 shares have been traded on the exchange so far.

The BSE Group 'A' stock, with a face value of RS 2, recorded its 52-week high of RS 1,672.20 on October 23, 2025, while its 52-week low of RS 1,165.55 was registered on April 2, 2026. Over the past week, the stock has traded between RS 1,426.20 and RS 1,377.00.

Cipla currently commands a market capitalisation of approximately RS 1,11,637.96 crore. Promoters hold 29.21% of the company, while institutional and non-institutional investors own 54.83% and 15.95%, respectively.

In a significant business development, Cipla's wholly owned subsidiary Invagen Pharmaceuticals Inc. has partnered with Qilu Pharmaceutical Co. for the exclusive licensing and supply of QL2107, a biosimilar of Keytruda (pembrolizumab), in the United States.

Under the agreement, Qilu Pharmaceutical will oversee the product's development, regulatory submissions and supply. Cipla USA Inc. will handle commercialisation in the agreed US territory, supported by its established commercial network. The partnership is aimed at expanding access to advanced biologic treatments for cancer patients.

Cipla operates across the pharmaceutical sector, with activities spanning the manufacturing, development and marketing of branded and generic medicines as well as Active Pharmaceutical Ingredients (APIs).

Ramco Systems witnessed positive movement on the BSE, trading at RS 600.70, marking a rise of RS 14.35 or 2.45% compared with its previous close of RS 586.35.

The stock began the session at RS 598.05 and moved to an intraday high of RS 605.05, while its lowest level so far stood at RS 597.00. Around 3,096 shares have been traded on the exchange.

The BSE Group 'B' stock, having a face value of RS 10, has recorded a 52-week high of RS 968.20 on July 7, 2026, and a 52-week low of RS 342.50 on March 30, 2026.

Over the past week, the stock has traded between RS 569.75 and RS 605.05. The company currently commands a market capitalisation of approximately RS 2,254.30 crore.

Promoters hold 55.51% of the company's equity, while institutional investors and non-institutional investors hold 13.22% and 31.25%, respectively.

Strategic Collaboration with Safran Helicopter Engines

Ramco Systems has entered into a Memorandum of Understanding (MoU) with Safran Helicopter Engines, a major global manufacturer of rotorcraft turbine engines. The partnership aims to facilitate the smooth transfer of Safran engine-related information into Ramco Aviation Software.

Under the proposed integration, information generated after engine shop visits will be transferred directly from Safran's systems into the Maintenance Information System (MIS) within Ramco Aviation Software. This is expected to minimise manual data entry for helicopter operators and help maintenance teams devote more time to aircraft availability and operations.

The collaboration is also expected to pave the way for Safran Helicopter Engines to award Ramco Systems the EngineLife Connect label, which recognises connectivity solutions compatible with Safran's products and services.

As part of the agreement, both companies will explore the automated transfer of key information, including engine configurations, usage data and maintenance events, into Ramco Aviation Software. The initiative is intended to enhance data accuracy, consistency and efficiency across aviation maintenance activities.

The companies will additionally assess suitable data exchange formats and develop operational procedures to maintain compatibility between their systems over the long term.

Ramco Systems is an enterprise software and technology platform provider focused on cloud-based and mobile-enabled solutions. The company develops multi-tenant enterprise software designed to support digital transformation and operational efficiency across industries.

Shares of Rail Vikas Nigam Ltd (RVNL) were trading at RS 211.60 on the BSE, registering a gain of RS 2.10, or 1.00%, compared with the previous close of RS 209.50.

The stock opened at RS 212.40 and moved between an intraday high of RS 213.40 and a low of RS 209.80. Around 239,776 shares had changed hands on the exchange during the session.

The BSE Group ‘A’ company, which has a face value of RS 10 per share, has recorded a 52-week high of RS 400.90, reached on December 29, 2025. Its 52-week low stands at RS 203.95, touched on September 2, 2026. Over the past week, the stock has traded between RS 203.95 and RS 214.00.

At the current market price, RVNL’s market capitalisation stands at approximately RS 43,806.27 crore. Promoters hold 72.84% of the company, while institutional and non-institutional investors own 9.02% and 18.14%, respectively.

RVNL Wins Lowest Bidder Status for RS 404.88 Crore Railway Contract

Rail Vikas Nigam has been declared the Lowest Bidder (L1) by East Coast Railway for a major infrastructure project covering the Khurda Road–Gangadharpur and Khurda Road–Vizianagaram sections.

The contract involves a broad range of railway infrastructure activities, including roadbed construction, minor and major bridges, RUBs/LHS, building works, ballast supply, permanent-way linking and associated works. The scope also includes utility shifting, signalling and telecommunication-related works, electrification activities, power supply arrangements, and modification or shifting of HT and LT lines.

The project carries an estimated value of RS 404.88 crore, inclusive of GST, and is scheduled for completion within 30 months.

About Rail Vikas Nigam

Rail Vikas Nigam operates as an extended arm of the Ministry of Railways and undertakes a wide range of railway infrastructure projects across India. Its activities include construction of new railway lines, line doubling, gauge conversion, railway electrification, metro projects, workshops, major bridges, cable-stayed bridges and institutional buildings, among other infrastructure works.

Fredun Pharmaceuticals is witnessing positive movement on the BSE, with its shares trading at RS 1495.00, gaining RS 6.80 or 0.46% over the previous close of RS 1488.20.

The stock began the session at RS 1524.50 and moved between an intraday high of RS 1524.50 and a low of RS 1484.00. A total of 1,217 shares have been traded on the exchange so far.

The company is classified under the BSE Group 'B' category and has a face value of RS 10 per share. Fredun Pharmaceuticals recorded its 52-week high of RS 1600.00 on August 17, 2026, while its 52-week low was RS 390.18 on September 22, 2025.

Over the past week, the stock has touched a high of RS 1529.00 and a low of RS 1433.00. The company's current market capitalisation stands at approximately RS 2466.32 crore.

In terms of shareholding, promoters own 44.57% of the company, while institutions hold 4.00% and non-institutional investors account for 51.43%.

Meanwhile, Fredun Pharmaceuticals has introduced PAWTALKS, a new platform focused on pet and animal healthcare. The initiative aims to create a space where veterinary professionals, researchers, pet owners, animal welfare representatives, and industry experts can exchange knowledge and discuss developments across the animal healthcare sector.

PAWTALKS is being positioned as more than a conventional pet-focused podcast. The platform is intended to provide accessible and reliable information for a broad audience, including new pet parents, experienced caregivers, veterinary students, and professionals working in animal healthcare.

The content will address several areas of pet care, such as preventive treatment, diagnostics, nutrition, animal behaviour, new veterinary technologies, welfare initiatives, and experiences from members of the veterinary community.

The platform is initially being rolled out across YouTube and Instagram. Its content format will include detailed expert discussions, short educational videos, myth-versus-fact features, expert-led explanations, behind-the-scenes material, and interactive initiatives aimed at engaging the pet-care community.

Fredun Pharmaceuticals operates in the pharmaceutical manufacturing sector and produces a range of pharmaceutical products.

Lords Chloro Alkali witnessed positive movement on the BSE, with its shares trading at RS 141.60, marking a gain of RS 3.70 or 2.68% over the previous close of RS 137.90.

The stock opened at RS 139.30 and moved between a low of RS 139.30 and a high of RS 141.60 during the session. A total of 152 shares changed hands on the BSE.

The company’s BSE Group ‘B’ stock has a face value of RS 10. Over the past 52 weeks, the scrip has recorded a high of RS 235.80 on October 21, 2025, while its 52-week low stands at RS 108.45, recorded on March 30, 2026. During the previous week, the stock traded between RS 133.70 and RS 145.85.

Lords Chloro Alkali currently has a market capitalisation of approximately RS 395.14 crore. Promoters hold a 74.97% stake in the company, while institutional investors and non-institutional shareholders hold 0.08% and 24.95%, respectively.

21 MW Captive Solar Plant Commissioned

Lords Chloro Alkali has announced the successful commissioning and commencement of operations of its 14.5 MW AC / 21 MW DC captive solar photovoltaic power plant, along with a 1.672 MWh Battery Energy Storage System (BESS) at Lunkaransar in Rajasthan’s Bikaner district.

The renewable energy project was commissioned on September 2, 2026, following successful grid synchronization and completion of the required certification process with the competent authorities.

The solar facility has been developed for captive consumption and is expected to raise the company’s renewable energy usage to around 40%. The initiative is also aimed at reducing reliance on comparatively expensive grid electricity, improving long-term energy cost efficiency and advancing the company’s sustainability goals.

Following the commissioning, Lords Chloro Alkali’s total installed captive and group-captive renewable energy capacity has increased to 47 MW DC.

About Lords Chloro Alkali

Lords Chloro Alkali is engaged in manufacturing a range of chemical products, including Caustic Soda, Chlorine, Hydrogen, Hydrochloric Acid (HCL), Stable Bleaching Powder and Tri Chloro Ethylene. The company primarily serves customers and markets across North India.

Lumino Industries made a strong debut on the BSE, with its shares opening at Rs 109.00, marking a gain of Rs 27.00 or 32.93% over the issue price of Rs 82.00.

Following the listing, the stock extended its gains and was trading at Rs 112.89, representing an increase of Rs 30.89 or 37.67% compared with the IPO price.

During the session, the shares touched a high of Rs 114.36 and a low of Rs 106.48. Around 84.20 lakh shares had changed hands on the BSE so far.

The company's public issue was available for subscription between August 27, 2026 and August 31, 2026, and received an overwhelming response, with the issue subscribed 124.02 times. The IPO was priced at Rs 82 per share, the upper end of the Rs 72-Rs 82 price band.

Lumino Industries operates as an integrated, product-focused engineering, procurement and construction (EPC) company in India. Its business includes the manufacturing and supply of conductors, power cables, electrical wires, as well as specialised products and components catering to the country's expanding power transmission and distribution sector.

Shares of Inox Wind advanced during Thursday’s trading session, gaining 2.02% to Rs 71.84 on the BSE, compared with the previous close of Rs 70.42.

The stock opened at Rs 71.98 and moved between Rs 70.56 and Rs 72.28 during the session. Around 1,003,794 shares changed hands on the BSE so far.

The BSE Group ‘A’ company, with a face value of Rs 10 per share, has recorded a 52-week high of Rs 159.25 on October 29, 2025, while its 52-week low stands at Rs 68.04, touched on September 2, 2026.

Over the past week, the stock has traded between Rs 68.04 and Rs 72.89. The company currently commands a market capitalisation of approximately Rs 12,403.56 crore.

Promoters hold a 44.18% stake in Inox Wind, while institutional investors and non-institutional investors own 24.43% and 31.39%, respectively.

The company has received a 100 MW turnkey wind power project from Indian Oil Corporation, one of India’s largest oil marketing companies. As part of the contract, Inox Wind will manage the project from start to finish, covering the supply of wind turbine generators, engineering, procurement and construction (EPC), project implementation, and operations and maintenance services after commissioning.

The turnkey contract also includes long-term post-commissioning O&M support. The new order further broadens Inox Wind’s customer base across commercial and industrial customers, public sector undertakings (PSUs), and independent power producers (IPPs).

Inox Wind is part of the INOXGFL Group and operates as a major provider of wind energy solutions in India. The company offers services and solutions to IPPs, utilities, PSUs and corporate investors.

Indo-National shares were trading at RS 329.80 on the BSE, registering a gain of RS 8.00, or 2.49%, compared with the previous close of RS 321.80.

The stock began the session at RS 329.80 and moved between RS 328.25 and RS 329.80 during the trading session. A total of 9 shares had changed hands on the exchange so far.

The company is part of the BSE Group 'B' category and has a face value of RS 5 per share. Over the past 52 weeks, the stock has recorded a high of RS 505.00 on September 4, 2025, while its 52-week low was RS 255.00 on April 1, 2026.

During the previous week, Indo-National shares traded between a high of RS 335.00 and a low of RS 319.95. The company's current market capitalisation stands at approximately RS 240.90 crore.

Promoters hold a 65.35% stake in the company, while non-institutional investors account for the remaining 34.65%.

In a recent development, Indo-National has invested RS 50.03 lakh in Medcuore Medical Solutions (MMSPL) through the subscription of additional equity shares. The investment has increased the company's stake in MMSPL by 0.78%, taking its overall holding in the medical solutions company to 61.87%.

The investment is aimed at supporting the expansion of MMSPL's business, creating additional revenue opportunities and contributing to future profitability. Prior to this latest investment, Indo-National had invested a cumulative RS 49.93 lakh through the subscription of equity shares in MMSPL.

Formerly known as Nippo Batteries Co., Indo-National is an India-based company engaged in the marketing of LED torch lights and related lighting products designed to meet varied consumer requirements.

Mankind Pharma shares were trading at RS 2372.00 on the BSE, gaining RS 12.00, or 0.51%, compared with the previous close of RS 2360.00.

The stock began the session at RS 2323.15 and moved between an intraday high of RS 2382.50 and a low of RS 2323.15. A total of 10,618 shares had changed hands on the exchange so far.

The BSE Group 'A' stock, with a face value of RS 1, has recorded a 52-week high of RS 2670.00, reached on September 19, 2025, and a 52-week low of RS 1909.90, recorded on March 23, 2026.

Over the past week, the stock has traded between RS 2323.15 and RS 2441.15. The company's current market capitalisation stands at approximately RS 97,612.88 crore.

As per the shareholding pattern, promoters own 72.63% of the company, while institutional investors hold 24.80% and non-institutional investors account for the remaining 2.57%.

In a significant corporate development, Mankind Pharma has completed the sale of its entire 100% holding in Broadway Hospitality Services (Broadway) to AKRK Projects LLP and its partners. Following the transaction, Broadway has ceased to remain a wholly owned subsidiary of Mankind Pharma with effect from August 31, 2026.

The company's Board of Directors had earlier approved the proposed divestment at its meeting on July 11, 2026. The transaction was cleared for a total consideration of RS 49.00 crore.

Mankind Pharma operates in the pharmaceutical sector, with a portfolio covering medicines for multiple acute and chronic therapeutic segments. The company is also involved in the development, manufacturing and marketing of consumer healthcare products.